The value of Sonoclot detection technology to guide the clinical medication of the perioperative anticoagulation and antiplatelet therapy in patients with acute myocardial infarction undergoing emergent PCI
| Autor: | Fu-Heng Chen, Dong-Xia Wang, You-Rui Ji, Wu-Xiao Yang, Ji-Rong Wang, Chun-Lin Lai |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.drug_class Activated clotting time acute myocardial infarction Low molecular weight heparin 030204 cardiovascular system & hematology Thrombin time antiplatelet 03 medical and health sciences 0302 clinical medicine Immunology and Microbiology (miscellaneous) Internal medicine Sonoclot detection technology Medicine Myocardial infarction anticoagulation Prothrombin time medicine.diagnostic_test business.industry 030208 emergency & critical care medicine Articles General Medicine Clopidogrel medicine.disease Thrombosis Surgery Cardiology business medicine.drug Partial thromboplastin time |
| Zdroj: | Experimental and Therapeutic Medicine |
| ISSN: | 1792-1015 1792-0981 |
| DOI: | 10.3892/etm.2017.4336 |
| Popis: | The value of Sonoclot detection technology to guide the clinical medication of the perioperative anticoagulation and antiplatelet therapy in patients with acute myocardial infarction (AMI) undergoing emergent percutaneous coronary intervention (PCI) was estimated. One hundred and twenty-eight patients were randomly divided into control group and observation group with 64 cases in each group. Control group adopted routine blood coagulation indexes, including prothrombin time, activated partial thromboplastin time, fibrinogen and plasma thrombin time, platelet count and platelet aggregation turbidity analysis; observation group adopted Sonoclot detection technology, including activated clotting time, coagulation rate and platelet function. Anticoagulant therapy selected was of low molecular weight heparin calcium perioperatively, intraoperative unfractionated heparin, and clopidogrel (75 mg) combined with aspirin enteric-coated tablets (100 mg) as antiplatelet drugs. The therapy was administered in accordance with blood coagulation results. The blood coagulation time, postoperative creatine kinase isoenzyme MB, cardiac troponin I and B-type natriuretic peptide levels in the observation group are significantly lower than those in the control group (P0.05). The incidence of recurrent myocardial infarction, microembolism, acute and subacute thrombosis and bleeding events in the observation group are significantly lower than those in the control group (P0.05). Whereas, in the observation group, there is significant difference in coagulation indexes of the patients with thrombosis events or bleeding events or no event (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|